H. pylori Treatment Guidelines

First-Line Treatment

The American Gastroenterological Association recommends bismuth quadruple therapy for 14 days as the first-line treatment for H. pylori infection, consisting of a PPI twice daily, bismuth subsalicylate, metronidazole, and tetracycline, achieving 80-90% eradication rates 1, 2, 3
Bismuth quadruple therapy is effective even against metronidazole-resistant strains due to bismuth's synergistic effect with other antibiotics, with eradication rates of 80-90% 2, 3
The standard regimen consists of bismuth, metronidazole, tetracycline, and PPI twice daily for 14 days, with higher doses of metronidazole improving eradication rates 1, 4, 5

Concomitant non-bismuth quadruple therapy is the preferred alternative, consisting of PPI twice daily, clarithromycin, amoxicillin, and metronidazole for 14 days, avoiding the pitfall of sequential therapy 1, 2, 3
Clarithromycin-based triple therapy should only be used in areas with documented clarithromycin resistance <15%, as resistance develops rapidly after exposure 2, 3

High-dose PPI twice daily is mandatory and increases eradication efficacy by 6-10% compared to standard once-daily dosing, with esomeprazole or rabeprazole 40mg twice daily increasing cure rates by an additional 8-12% 6, 3
Treatment duration of 14 days is superior to 7-10 day regimens, improving eradication success by approximately 5% 2, 6, 3

After failure of clarithromycin-containing therapy, either bismuth quadruple therapy or levofloxacin-containing triple therapy is recommended, with levofloxacin-based triple therapy consisting of PPI twice daily, amoxicillin, and levofloxacin for 14 days 6, 3
Levofloxacin should not be used empirically as first-line therapy due to rapidly rising fluoroquinolone resistance rates 2

After two failed therapies, H. pylori susceptibility testing should be performed to guide subsequent regimens, with molecular testing for clarithromycin and levofloxacin resistance available 1, 4, 5, 3
Rifabutin-based triple therapy is highly effective as rescue therapy after multiple treatment failures, consisting of rifabutin, amoxicillin, and PPI twice daily for 10-14 days 1, 2

Confirm eradication with urea breath test or monoclonal stool antigen test at least 4 weeks after completion of therapy and at least 2 weeks after PPI discontinuation, as serology should not be used to confirm eradication 6, 3

Probiotics can be used as adjunctive treatment to reduce antibiotic-associated diarrhea and improve patient compliance, but are of unproven benefit for improving eradication rates 2, 3

Never assume low clarithromycin resistance without local surveillance data, and avoid repeating clarithromycin if the patient has prior macrolide exposure for any indication 2
Avoid concomitant use of other antacids with PPIs during treatment, and carefully weigh the benefits of H. pylori eradication against the inconvenience and risks of repeated antibiotic exposure in vulnerable populations 1, 5

The American Gastroenterological Association and other major guidelines specify bismuth ~300 mg four times daily as the standard dose, emphasizing that this dosing is critical for achieving 80-90% eradication rates, with a strength of evidence supported by multiple studies 7, 8
The standard bismuth dosing is approximately 300 mg four times daily, and reducing to 232 mg three times daily represents a 42% dose reduction that is not supported by any guideline or evidence, as stated by the American College of Gastroenterology 7, 8

The 14-day treatment duration is mandatory and cannot be shortened, as 14-day therapy achieves 93-97% eradication rates compared to only 80-82% with 7-10 day regimens, according to the Toronto Consensus and Maastricht V/Florence guidelines 7, 8
Concomitant non-bismuth quadruple therapy may be considered as an alternative first-line regimen if nausea remains intolerable, with a 14-day treatment duration and clarithromycin resistance <15% in the region, as recommended by the American College of Gastroenterology 8

Higher metronidazole doses (1.5-2 g daily in divided doses) improve eradication rates even against resistant strains when combined with bismuth, and patients should take metronidazole with food in divided doses (three to four times daily) and avoid alcohol due to disulfiram-like reactions, as recommended by the American Gastroenterological Association 9
For patients with documented penicillin allergy, bismuth quadruple therapy is the first choice since it contains tetracycline rather than amoxicillin, and true anaphylaxis to penicillin is rare despite prevalent chart documentation, according to the American Gastroenterological Association 9
In the absence of anaphylaxis history, consider penicillin allergy testing to delist the allergy and enable amoxicillin use, as amoxicillin resistance remains extremely rare (<5%), as suggested by the American Gastroenterological Association 9

Dividing amoxicillin into at least three doses daily avoids low trough levels and improves efficacy, and adequate intragastric acid suppression is critical, as intragastric pH affects amoxicillin efficacy and half-life, as recommended by the American Gastroenterological Association 9
Avoid concomitant use of other antacids (H2-receptor antagonists) with PPIs during treatment, as this may interfere with PPI absorption and activation, according to the American Gastroenterological Association 9

After multiple failed eradication attempts, weigh the benefits of continued treatment against adverse effects and inconvenience, particularly in elderly patients, those with frailty, or those not at identifiably higher risk of complications (gastric cancer, peptic ulcer disease), and a shared decision-making approach is appropriate in these scenarios, as recommended by the American Gastroenterological Association 9